BIONET Valuation
Is 1784 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1784 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1784 (NT$92.8) is trading below our estimate of fair value (NT$144.62)
Significantly Below Fair Value: 1784 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1784?
Key metric: As 1784 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 1784's PE Ratio? | |
|---|---|
| PE Ratio | 84.3x |
| Earnings | NT$55.72m |
| Market Cap | NT$4.70b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.7x |
| Enterprise Value/EBITDA | 53.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 1784's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27x | ||
8403 ShareHope Medicine | 24x | n/a | NT$3.8b |
6637 Medical Imaging | 17.8x | n/a | NT$2.5b |
6879 TCI GENE | 49.3x | n/a | NT$1.3b |
3218 Universal Vision Biotechnology | 16.9x | 10.0% | NT$18.3b |
1784 BIONET | 84.3x | n/a | NT$4.7b |
Price-To-Earnings vs Peers: 1784 is expensive based on its Price-To-Earnings Ratio (84.3x) compared to the peer average (27x).
Price to Earnings Ratio vs Industry
How does 1784's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 1784 is expensive based on its Price-To-Earnings Ratio (84.3x) compared to the Asian Healthcare industry average (21.2x).
Price to Earnings Ratio vs Fair Ratio
What is 1784's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 84.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1784's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Universal Vision Biotechnology
NT$18.3b
Operates a chain of eye care clinics in Taiwan and China.
3218
NT$215.50
7D
1.9%
1Y
-27.1%
Hi-Clearance
NT$6.2b
Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.
1788
NT$138.50
7D
0.4%
1Y
2.6%
Pacific Hospital Supply
NT$6.5b
Manufactures, processes, and sells medical disposable products and equipment in Taiwan.
4126
NT$89.00
7D
-0.3%
1Y
6.0%